GEN 501
Alternative Names: GEN-501Latest Information Update: 06 Sep 2023
Price :
$50 *
At a glance
- Originator Genome & Company
- Class Bacteria; Skin disorder therapies
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Atopic dermatitis; Exanthema
Most Recent Events
- 28 Jun 2023 Preclinical trials in Atopic dermatitis in South Korea (Topical) (Genome & Company Pipeline, June 2023)
- 28 Jun 2023 Preclinical trials in Exanthema in South Korea (Topical) (Genome & Company Pipeline, June 2023)